Pulmonary and Hepatic Toxicity Due to Nitrofurantoin and Fluconazole Treatment

Annals of Pharmacotherapy

Volumn 38, Issue 4, 2004, Pages 612-616

  Linnebur, Sunny A ^a   Parnes, Bennett L ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Fluconazole; Hepatic toxicity; Nitrofurantoin; Pulmonary toxicity

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; CIMETIDINE; CITRATE CALCIUM; DIPHENHYDRAMINE; DOCUSATE SODIUM; FLUCONAZOLE; FLUOCINONIDE; FLUTICASONE; GENTAMICIN; IBUPROFEN; ITRACONAZOLE; MULTIVITAMIN; NITROFURANTOIN; POLYCARBOPHIL CALCIUM; TERAZOSIN; VITAMIN D;

AGED; ALLERGIC RHINITIS; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTICLE; BURNING SENSATION; CASE REPORT; CLINICAL FEATURE; COUGHING; DIAGNOSTIC IMAGING; DRUG WITHDRAWAL; DYSPNEA; ECZEMA; FATIGUE; HUMAN; IMAGE ANALYSIS; LABYRINTHITIS; LIVER TOXICITY; LONG TERM CARE; LUNG FUNCTION TEST; LUNG TOXICITY; MALE; ONYCHOMYCOSIS; PNEUMONIA; PRIORITY JOURNAL; RISK FACTOR; SYMPTOM; THORAX RADIOGRAPHY;

AGED; ANTIFUNGAL AGENTS; DRUG THERAPY, COMBINATION; FLUCONAZOLE; HUMANS; LIVER DISEASES; LUNG DISEASES; MALE; NITROFURANTOIN; ONYCHOMYCOSIS;

EID: 1542639422     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D306     Document Type: Article

References (16)

1. Hainer BL, White AA. Nitrofurantoin pulmonary toxicity. J Fam Pract 1981;13:817-23.
2. Schattner A, Von der Walde J, Kozak N, Sokolovskaya N, Knobler H. Nitrofurantoin-induced immune-mediated lung and liver disease. Am J Med Sci 1999;317:336-40.
3. Yalcin S, Sahin A, Yalcin B, Altinok G. Nitrofurantoin toxicity to both liver and lungs. Liver 1997;17:166-7.
4. Reinhart HH, Reinhart E, Korlipara P, Peleman R. Combined nitrofurantoin toxicity to liver and lung. Gastroenterology 1992;102:1396-9.
5. Kursbaum A, Rottenstreich E. Acute hepatitis and pneumonitis associated with nitrofurantoin. Harefuah 1990;119:427-8.
6. Lundgren R, Back O, Wiman LG. Pulmonary lesions and autoimmune reactions after long-term nitrofurantoin treatment. Scand J Respir Dis 1975;56:208-16.
7. Conklin JD. The pharmacokinetics of nitrofurantoin and its related bioavailability. Antibiot Chemother 1978;25:233-52.
8. Package insert. Macrodantin (nitrofurantoin macrocrystals). Cincinnati, OH: Procter & Gamble, June 2002.
9. Package insert. Macrobid (nitrofurantoin monohydrate/macrocrystals). Cincinnati, OH: Procter & Gamble, March 2003.
10. Package insert. Diflucan (fluconazole). New York: Roerig/Pfizer, June 1998.
11. Brammer KW, Coakley AJ, Jezequel SG, Tarbit MH. The disposition and metabolism of [14C] fluconazole in humans. Drug Metab Dispos 1991;19:764-7.
12. Package insert. Sporanox (itraconazole). Titusville, NJ: Janssen, February 2002.
13. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
14. Drayer DE. Active drug metabolites and renal failure. Am J Med 1977;62:486-9.
15. Hoener BA, Patterson SE. Nitrofurantoin disposition. Clin Pharmacol Ther 1981;29:808-16.
16. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther 2002;303:323-32.